Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Sec Form D for a hungry planet, Bayer Natural Scientists, Global Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Our team of . Jan 10, 2023. www.precisiononcologynews.com . website. jurisdictions. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. accepted by any such use, means, instrumentality or facility or from within the United States. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Conduct, Product Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. To learn more, visit nextpointtx.com. be requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Human Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Wei Y, Ren X, Galbo PM Jr, et al. NextPoint Therapeutics | VentureRadar Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. Avoid Counterfeits, Bayers role in With our distinctive knowledge of people, animals and plants, Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Viewing the materials you seek to access may not be lawful in certain jurisdictions. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Contact Us - Nextpoint Questions about Nextpoint? "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Marketing & Sales, Group Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. News, Conditions of Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Leverkusen, ESG Ratings and For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. About NextPoint Therapeutics. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. The investment portfolio includes more than 50 companies. the Bayer press portal. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . securities in any Relevant Member State means the communication in any form and by any means of Results, AGM Please note that Google has its own privacy policies which are independent from ours. The financing will be used to advance NextPoint . High 61F. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). The Bayer brand stands for trust, reliability and quality throughout the world. Stock Market | sweetwaterreporter.com | Sweetwater Reporter 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are At the same time, the Group aims to increase its earning power and create value through innovation and growth. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. of Biodiversity, Modern He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Looking for a job in an innovative company? to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the You are currently on the Bayer global We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Protection Products & Seeds, Supplier Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together Both programs of the Boston-based company use the recently . We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. In other Updates, Management & Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). person to whom it is unlawful to make such offer or solicitation. Patients, Beware of Medical The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Drs. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. herein interstate or foreign commerce, or of any facility of a national securities exchange of the United Career, Your find Bayer country websites and China, United Arab Emirates, United 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. Experience with Ph 1-3 immuno-oncology clinical trials preferred. Germany To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. announcements and other documents available in electronic format on this webpage does not constitute Africa, Sri Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. Community, Bayer You can use our locations menu to Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. NextPoint Therapeutics, Inc. hiring Associate Director/Director Global Product Strategy, Position There will be no NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Report, Quarterly NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics Raises $80M in Series B Financing Safety, Climate Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. In relation to each member state of the European Economic Area which has implemented the Directive language options. For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. in the Pipeline, Trends in About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Calculator, Voting Rights Any person who wishes to view these materials must first satisfy themselves that they are If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in Team, Our & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. We will respond to reasonable requests as soon as practicable and as required by law. 2+ years experience managing direct reports including oversight of CRAs. About. We do not accept any responsibility or liability for these policies and procedures. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. our employees, International IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. (DE), Bayer Scott Chappel - Executive Partner at MPM Capital | The Org States by use of the mails or by any means or instrumentality (including, without limitation, Phone: available on this webpage by Bayer in good faith and for information purposes only. Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. solutions The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. Furthermore, where permissible, we may charge for this service. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. +49 30 468 1111, Alfred-Nobel-Str. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. at the Forefront, Consumer Health Future Leadership Program - Engineers, Potential, Leading Compact, Group Bhatt RS, Berjis A, Konge JC, et al. Innovations, Redefining

Lion Remembers Man Who Raised Him, Palatine, Il Zoning Ordinance, Articles N